{"id":952854,"date":"2026-04-20T08:33:56","date_gmt":"2026-04-20T12:33:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/"},"modified":"2026-04-20T08:33:56","modified_gmt":"2026-04-20T12:33:56","slug":"when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/","title":{"rendered":"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech"},"content":{"rendered":"<div class=\"mw_release\">\n<p>AUSTIN, Texas, April  20, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=83nTgVDEyO9G1miJ8-TKE-h4xo_LPu0noV4PuQ51ggx0ek9BJ1rIZimFm0GqfGN33xCEOogThgpHdl7kY8EOxgiN5UFOSbzT5X54KptcFCmGGzbHtc5ASosujO8Da8osCZxHIbz8wPDs7Vx8H2MyzlPJ9JeGjdgFKWZEX0YJqct1k1VtQtxOPaWMgj26cBdJc3oTJiUwpMrZx3ZofJWOCKPIJwuT27lf2xKdlKbpUr3XjOsnGnk61a5fo8zk1axltdvW_TUPhqxnRzTYk0OCUUofrkrtOimDd4EfTt2qtl71oZ1btelyP53RJMOtSd2e\" rel=\"nofollow\" target=\"_blank\">BioMedWire Editorial Coverage<\/a>: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=psEC_8jXW1F-u51NcO0c8d4yS04LYvLOvBn2ooOj501Y6DM31O1KYxqaqKoAWQLHsWo0fgRYGeqyQAw8cYA3Xw==\" rel=\"nofollow\" target=\"_blank\">reinforced<\/a> by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc.\u00a0(OTCQB: OTLC) (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q6kdRMHnei7etJobCcIpx_INGDenEplkmz5ctmbWQNnRZXEzHirnC41D6IFoAz0nOiUNmehdA9K7sltFo_itIqYLzEvZllcyCmCkRTYA-ZTKfqdjZL0_-eZEoapbddTgdZW5MHk99_K1e2kHh0N4AQ==\" rel=\"nofollow\" target=\"_blank\">profile<\/a>), are keenly aware of this evolution and are leveraging their expertise as pioneers in this space. Through its diversified pipeline and strategic holdings, including a 45% ownership stake in GMP Bio, which was recently <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6Q2gPushwwcGwdR0HK6-1qfNzw35mRmse68l5AIYfsIGbH_C8kghU1fOpwGOs_SG2wpOvWvvfBwhqAFHb69SUQ==\" rel=\"nofollow\" target=\"_blank\">measured<\/a> at more than $1 billion enterprise value, the company exemplifies how advancing science can directly influence financial positioning. As the biotech sector increasingly aligns valuation with progress rather than revenue alone, Oncotelic provides a case study in how innovation is becoming a recognized asset class. Oncotelic joins an elite group of other key companies focused on\u00a0advanced biotech platforms that target disease at the genetic or molecular level, including <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mgCeeNdl6YXhPh6ulFC-0nTdD0-w65y6kAir8SqcfR6WGM0tl4TCtjKdLav1OMEBeHqg2FzWb0pAHx1uq8Qi0H70Kufvs-p-QowyAjINiJecikW3kiosXKYOSs-cS6k2i6v__S_0GEjhqLGo1Xlj1C2l-2_1iRCm_HMfNBhxYOjnE6IuKcF8qcxBJ_4oeHCM\" rel=\"nofollow\" target=\"_blank\"><strong>Sarepta Therapeutics Inc.<\/strong><\/a>\u00a0(NASDAQ: SRPT), <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n8mfYrjnbu0BeG0pKt6OnU8H0f7FyJoXrD_A5taBwSG8PGlLPDexrVh7unnfVuElEOMY-FUFGrthIQCJAP-zTMje8BaJLwKMFXlNaIqL_4LiCbMf6_Qpdj9vWrPeCbtHWXuscGtPIme8tYphyYoBTCrxYV0NEiP3lMxd29mUXTIyWEj6ddak0eRl-QCJ6I26hf4j4jSDOC9EUbVHVChjwg==\" rel=\"nofollow\" target=\"_blank\"><strong>Alnylam Pharmaceuticals Inc.<\/strong>\u00a0<\/a>(NASDAQ: ALNY), <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=slwEA7Aia5RaRLhhGGzxlM1xj-Oi1fDpuyHQsymKdM1KuoYhwbswW30c9mBpm3Tc28jZubX5MuEsXk-J2bThBaJM6V_-bULAHeuUQfs3UxYxK4e5BqKwFfh9s4MrBqA6cjpfbMVQOs34vN4K0ysjq8A1pvP0Rs0fk7K70ChRN-kM5c0tiGhMyub2NdwuCnGoItythnfIiFeHwPTtaInLSg==\" rel=\"nofollow\" target=\"_blank\"><strong>Arcturus Therapeutics Holdings Inc.<\/strong><\/a> (NASDAQ: ARCT) and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=svkdz31OF3_DfkfMhBKELpci39gY_4cXRLe_0R9A4HbR-OFhM-CaMYswD8am5R711OcpI4eEroPY_T2riJ7SzRw9cYm8nvzJSuBULKw04AfjJQYYS1RQ5gyykR-rvgwLG4vljDyGCEeqKYUFjnn0asbVCxDnUFazguBdclQ-U0Zjq83ktWY67stBl6clJPQY\" rel=\"nofollow\" target=\"_blank\"><strong>Denali Therapeutics Inc.<\/strong><\/a> (NASDAQ: DNLI).\u00a0<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>The biotechnology sector is evolving from a model centered on long-term R&amp;D investment into one where scientific advancement can be reflected as measurable financial value.<\/strong>\n        <\/li>\n<li>\n          <strong>As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization.<\/strong>\n        <\/li>\n<li>\n          <strong>The rise of fair-value accounting in biotechnology is enabling companies to provide more transparent and timely representations of asset value. <\/strong>\n        <\/li>\n<li>\n          <strong>Institutional investors are increasingly recognizing clinical-stage biotech assets as investable opportunities, even in the absence of current revenue.<\/strong>\n        <\/li>\n<li>\n          <strong>Oncotelic Therapeutics operates directly within this convergence, combining oncology-focused drug development with AI-enabled platforms and strategic manufacturing exposure.<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p>Click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4J4MI-PnX2frVStDfV8IMmegqpyerow7sf3VARPwhe-Bi-xvPhWXt2yuIFGElztZKDN01t4uIBGznKroykHL5g==\" rel=\"nofollow\" target=\"_blank\">here<\/a> to view the custom infographic of the Oncotelic Therapeutics editorial.<\/p>\n<p>\n        <strong>Scientific Progress Is Becoming Financial Value<\/strong>\n      <\/p>\n<p>The biotechnology sector is evolving from a model centered on long-term R&amp;D investment into one where scientific advancement can be reflected as measurable financial value. Historically, investors relied heavily on discounted cash-flow projections tied to eventual commercialization, often leaving a gap between innovation and valuation. However, the adoption of fair-value frameworks under U.S. GAAP is beginning to bridge that gap by allowing companies to reassess asset value as clinical milestones are achieved.<\/p>\n<p>Under <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xJDbSkmJ7RR83xIoz5j9BkepjXvSA5prbHW-31S7KdKjtkwAnjZKVZOq16MXjmnVG5ynFN7k6V5YoHRb7lfj6Vq7SjsIquzME8rg41EiO29BSPm_wLtLOzyi7kmExRYN\" rel=\"nofollow\" target=\"_blank\">Financial Accounting Standards Board guidance<\/a>, particularly ASC 820, companies can measure the fair value of assets, including illiquid or early-stage investments, based on observable and unobservable inputs. This includes Level 3 assets, which are commonly used in biotech to value pipeline-stage programs and strategic investments. These frameworks allow companies to incorporate scientific progress, regulatory advancement and probability of success into financial reporting.<\/p>\n<p>Advisory firms such as Deloitte and PwC <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Uf572J-0kP1xOAtfnEl9IBDD4bonEKTjhMF-ckQVh1t3Tl56BQUzFNGgIMDtlx9fQBaZ866QxWFhOsGlXH94gw==\" rel=\"nofollow\" target=\"_blank\">note<\/a> that in life sciences, valuation can reflects forward-looking indicators such as clinical progress and expected commercialization potential, as GAAP fair-value frameworks require assets to be measured based on market participant assumptions about future economic benefits. This approach aligns financial reporting more closely with operational reality, particularly in sectors where revenue may lag innovation by years.<\/p>\n<p>This shift is particularly relevant for\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TWVAJiGtch29AggIRSWfdmykhbgWary9ZxFrra2zFJ3nuTzM7VuuHtypik07qJD0Fv7Qk_HMyzx6CsaTlm4NXbSFs-J4pDhOJufd84-4r4I=\" rel=\"nofollow\" target=\"_blank\">Oncotelic Therapeutics<\/a>, which operates in a space where pipeline advancement is a primary driver of value. By aligning its financial reporting with the progression of its therapeutic programs and strategic investments, the company reflects the broader industry movement toward recognizing science itself as an asset.<\/p>\n<p>\n        <strong>Pipeline Proximity Drives Valuation Inflection<\/strong>\n      <\/p>\n<p>As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization. This phenomenon \u2014 often referred to as valuation inflection \u2014 is well documented across the biotech industry. Late-stage assets, particularly those approaching regulatory approval, tend to command a disproportionate share of enterprise value.<\/p>\n<p>According to\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtFx0vS4MdkI2Qobh1FOJNcFGp-kIsLL6lFmtOp3DncKZUMUwz36N2cEb0hw7EskfVXJ4EO5iM-XrTbxGy5zlbKwuLnxVICyCo4F7ZnRjQc=\" rel=\"nofollow\" target=\"_blank\">McKinsey &amp; Company<\/a>, value creation in biopharma is heavily concentrated in late-stage assets, with companies generating the majority of returns as products progress toward approval and commercialization, reflecting reduced risk and clearer revenue visibility. Additional industry analysis <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kXdpkZJnoPXDSmOe-Qnlzfl2kBEefY6GTv-B0jDoD3gAvac37EfHr3x-aH9f1hVGJwxZmaroagzMeUdoP1MzlA==\" rel=\"nofollow\" target=\"_blank\">shows<\/a> that assets approaching commercialization drive significant increases in company valuation due to higher probability of success and expected market entry.<\/p>\n<p>This dynamic highlights a critical change in how investors assess biotech companies. Rather than focusing solely on current revenue or earnings, market participants increasingly evaluate the maturity and trajectory of pipeline assets. As a result, companies with strong late-stage programs can experience significant valuation increases even before generating commercial sales.<\/p>\n<p>For\u00a0Oncotelic Therapeutics, this trend is particularly relevant, given the company\u2019s focus on advancing oncology therapeutics and its strategic positioning within high-value development pathways. As its programs progress and move closer to commercialization, the company\u2019s valuation profile reflects the broader industry shift toward pipeline-driven value creation.<\/p>\n<p>\n        <strong>Fair-Value Accounting Gains Ground in Biotech<\/strong>\n      <\/p>\n<p>The rise of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wAK1vffo-ALxU9apWKfAtYGvndpUhpeW-v4a-9B8tnNV2uIsJ64PIiUPa0zdd11rOUJaDRntqW0aDSKYqbeUjSe0aGKU9itbaXDZZRlohIA=\" rel=\"nofollow\" target=\"_blank\">fair-value accounting<\/a> in biotechnology is enabling companies to provide more transparent and timely representations of asset value. Under GAAP, Level 3 valuations are used to measure assets without observable market prices, relying on models that incorporate forward-looking assumptions such as expected cash flows and probability-weighted outcomes.<\/p>\n<p>The ASC 820 framework <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jx9zLYejEj2_5E4czlgAcrblcSXT0C30Ctl0kwFrIJHq6BYhvWtHPRyUGniesxH6aAtzcY9zCTZbnfYqq1BFfQ==\" rel=\"nofollow\" target=\"_blank\">defines<\/a> fair value as the\u00a0exit price\u00a0that would be received to sell an asset in an\u00a0orderly transaction\u00a0between market participants at the measurement date. It provides a structured hierarchy for the\u00a0subsequent measurement\u00a0of complex, illiquid assets using\u00a0market-participant assumptions\u00a0and the best available information, aligning financial reporting with a\u00a0current, market-based view\u00a0of an asset&#8217;s value.<\/p>\n<p>Oncotelic Therapeutics exemplifies this approach through the remeasurement of its stake in GMP Bio, which reflects an approximate $1 billion-plus enterprise value. This demonstrates how clinical and strategic progress can translate directly into balance sheet strength, reinforcing the concept of science as a financial asset.<\/p>\n<p>\n        <strong>Institutional Capital Embraces Prerevenue Biotech<\/strong>\n      <\/p>\n<p>Institutional investors are increasingly recognizing clinical-stage biotech assets as investable opportunities, even in the absence of current revenue. This shift reflects a growing confidence in structured valuation methodologies that incorporate scientific progress, rather than relying solely on traditional financial metrics.<\/p>\n<p>Many biotechnology companies are <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ALj54Q3yOGzWpcdftKKly7uV7-5tiS2dZoj6_bzdAkq1e9s0oaQJiukS3OWuWfq_BNsNW36nIpx6k0omuCgQzQ==\" rel=\"nofollow\" target=\"_blank\">valued<\/a> primarily on the strength of their pipelines rather than their existing revenue streams, reflecting the long development timelines and lack of early-stage earnings typical of the sector. Instead, valuation is closely tied to scientific progress, with factors such as clinical development stage, probability of success and regulatory milestones serving as key drivers of equity value. This <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pnrCNQ6AqHRu9qbA8m1wJdEHlLZmpSj2yFU8eg7UCdAh8hUR_4-6VnivbLBRyIFPSicDacAHJ_FN4OTBHxU2Ag==\" rel=\"nofollow\" target=\"_blank\">approach<\/a> underscores that value creation in biotech often occurs well before commercialization, as investors increasingly rely on milestone-based and probability-adjusted models to assess future potential.<\/p>\n<p>Within this context,\u00a0Oncotelic Therapeutics is positioned to benefit from growing institutional interest in pipeline-driven valuation. Its diversified portfolio and strategic investments align with the types of assets that are increasingly attracting capital in the biotech sector.<\/p>\n<p>\n        <strong>AI, GMP and Commercial Readiness Converge<\/strong>\n      <\/p>\n<p>Advancements in AI-driven drug development and GMP-compliant manufacturing are accelerating timelines and improving scalability across the biotech industry. These technologies enable more efficient clinical development, better data analysis and streamlined production processes, reducing both time and cost to market.<\/p>\n<p>AI is increasingly being used to identify drug targets, optimize trial design and analyze complex datasets, improving the probability of success in clinical programs. At the same time, GMP-compliant manufacturing platforms are enabling more reliable and scalable production, which is critical as therapies move toward commercialization.<\/p>\n<p>Research <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5BIyXWGjuW9U9HMVvsRDECBIGLJVr6_NibNkgjQ7OUa39uMdWdWaE-oiU0uBfPMF7nq3GYvYhhKQt0WG2O-ysQ==\" rel=\"nofollow\" target=\"_blank\">indicates<\/a> that data-driven approaches are becoming central to biopharma value creation, with AI and advanced analytics playing a key role in accelerating development timelines. These advancements enhance the reliability of valuation models by reducing uncertainty and improving execution. This convergence of AI, manufacturing and clinical development is reshaping how value is created and measured in biotech. Companies that can integrate these capabilities are better positioned to advance therapies efficiently while maintaining regulatory compliance.<\/p>\n<p>Oncotelic Therapeutics operates directly within this convergence, combining oncology-focused drug development with AI-enabled platforms and strategic manufacturing exposure. This integrated approach supports both scientific advancement and financial valuation, positioning the company within one of the most significant growth trends in the biotechnology sector.<\/p>\n<p>The biotechnology sector is entering a new phase in which scientific progress is no longer viewed solely as a cost center but as a measurable financial asset. As fair-value accounting, pipeline maturity and AI-driven development reshape the industry, the traditional gap between innovation and valuation is narrowing.<\/p>\n<p>Companies such as\u00a0Oncotelic Therapeutics\u00a0illustrate how this transformation is unfolding in real time, demonstrating that clinical advancement can materially strengthen financial positioning even before revenue generation begins. As investors increasingly focus on pipeline-driven value, the ability to translate science into measurable economic impact is becoming one of the defining characteristics of modern biotech.<\/p>\n<p>\n        <strong>From Research Spend to Revenue-Ready Assets<\/strong>\n      <\/p>\n<p>A new wave of biotechnology innovation is increasingly blurring the line between scientific progress and financial value creation. As drug candidates targeting disease at the genetic and molecular level advance through clinical development in 2026, progress is no longer viewed solely as research expenditure but as a measurable and evolving asset. Recent updates across the sector highlight how advancements in RNA interference, gene therapy and targeted delivery platforms are not only improving clinical outcomes but also enhancing the underlying value of biotech pipelines.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mgCeeNdl6YXhPh6ulFC-0nTdD0-w65y6kAir8SqcfR5gY29xv57iad3uwQnJb3ETHpML8H-27RY_3tr-BeYJNGhrjRwDBRVBGloo_YdqBJYHvltQ1VfoJniYfc3V8BwsRnsfyVwUN4l5e786GwTlYQmNZAD0bVdXSH5KjogcWmWok18Qlqjw2tn57ORj1PVm\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Sarepta Therapeutics Inc.<\/strong><br \/>\n        <\/a>\u00a0(NASDAQ: SRPT) <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GS3ES-YaU-fDbz37Ymu2RtnCsh3UqqEMNg5qU-gHBMFTJmr7z8lKPO1bU-cqNy-A0PV6igEA2eZBsnw0zwETbw==\" rel=\"nofollow\" target=\"_blank\">announced<\/a> approval of its clinical trial application for SRP-1005, its investigational treatment for Huntington\u2019s disease. Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investigational small interfering RNA (siRNA) therapeutic. INSIGHTT is a phase 1, multicenter, dose-escalation study that will evaluate the safety and tolerability of subcutaneous dosing of SRP-1005 in approximately 24 participants.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n8mfYrjnbu0BeG0pKt6OnU8H0f7FyJoXrD_A5taBwSGJ3td1mHewkpryL1gZS2ENLVv-23SUuo-3GFYCtxWDRYuzRnjkOAQhDXCtg09xCuxl4lzlSvShzLh88UlmcI6sUlOTJkFE-yhAN6hsEkG_S5dQWbJHMzXOLuS6arEkaLJBxV3JVS7Liu8cE7HeKGhz2C-zcoY6EklLgHMIHUwK-g==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Alnylam Pharmaceuticals Inc.<\/strong><br \/>\n        <\/a>\u00a0(NASDAQ: ALNY) <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Dh-WRDwnWUAlq2LfXdDD_L_pU2GcdBb0VCuV_60W6bcnTZ4UosZk9NKhPBEpyAhneBD1UAvttKa0z7iAWbE2Q==\" rel=\"nofollow\" target=\"_blank\">reported<\/a> new clinical and real-world data from its cardiovascular (CV) portfolio. The data was presented at the\u00a0American College\u00a0of Cardiology\u2019s Annual\u00a0Scientific Session and Expo\u00a0(ACC.26). The new data continues to support the benefits of\u00a0vutrisiran in transthyretin amyloid cardiomyopathy (ATTR-CM), as well as the potential of\u00a0zilebesiran for hypertension, underscoring the versatility of RNAi therapeutics across cardiovascular diseases.\u00a0<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=slwEA7Aia5RaRLhhGGzxlM1xj-Oi1fDpuyHQsymKdM3ND8_o8wz2RuuIEYuQIyjnwaMLnF5OYLM4sgGECwVCmJMV3TbfJQp1W2G8O4TJ1g05gvsVOwCxPcUOawp9xndIYr8ld-GBkuYRtztd9REnJzhvZmStOELgTlP3HY_d8ReK-YRlDJcZ9Y5iqGoGCrRoR-LVd2JsUe6IgZxjyHG6xA==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Arcturus Therapeutics Holdings Inc.<\/strong><br \/>\n        <\/a> (NASDAQ: ARCT) is advancing a suite of messenger RNA (mRNA)\u2013based therapies. The company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X4HML0wZbRf8twSYmujFCNgR5iMclyPm8ZIZ12ubAy4VjbjJft0P7RyV4zOLYMsh4cBl8dcPNaSRO73niTe2VA==\" rel=\"nofollow\" target=\"_blank\">Q4 update<\/a> highlights progress in both rare diseases and vaccine platforms, including its lead candidate,\u00a0ARCT-032, an inhaled mRNA therapy for cystic fibrosis, which has demonstrated favorable safety and tolerability and is advancing into a phase 2 clinical study expected to begin in 2026.\u00a0In addition, the update noted advancement with its ARCT-810 program for ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder, with ongoing regulatory interactions aimed at supporting future pivotal studies.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=svkdz31OF3_DfkfMhBKELpci39gY_4cXRLe_0R9A4HZ2Jho-cITxzVk-5EcK9kCPG05SWT6scuUeGaids06WYZlHomevU_GRQr1vNwIsA7S-xHQqDjVB8cnPDzVm5OsphCD3LzVtBiguxzuUrklzMgVqoVW4IIQQjUPx9FbTFnt9snwvAwVIc01bDdLclem8\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>Denali Therapeutics Inc.<\/strong><br \/>\n        <\/a> (NASDAQ: DNLI) is <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x_or4uJnW90p6qpfokpNvdMRWPbPui2NvFNV3_by0uOkU-cPJLiW7LuMrfOwCEgHCLHOJX91j5EYERGa9sOO9TSiI8gn7ZW7EHudaRG00cE=\" rel=\"nofollow\" target=\"_blank\">making significant progress<\/a> in 2026 with its TransportVehicle(TM) platform. The platform is designed to enable the delivery of biologics across the blood-brain barrier, one of the most persistent challenges in treating neurological diseases. The company has outlined 2026 as a pivotal year, with plans to deliver its\u00a0first TransportVehicle-enabled medicine to patients\u00a0and advance two TV-enabled programs into clinical studies for Alzheimer\u2019s disease and a program for Pompe disease.<\/p>\n<p>These latest developments underscore a broader industry transition from discovery to execution, where scientific innovation is increasingly quantified in financial terms. As genetic and molecular therapies move closer to commercialization, the ability to demonstrate clinical efficacy, scalability and delivery precision is translating into tangible asset value within company pipelines. This convergence of science and finance is reshaping how biotechnology is evaluated, positioning advanced therapeutic platforms not just as research initiatives, but as structured, value-generating assets.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TWVAJiGtch29AggIRSWfdmykhbgWary9ZxFrra2zFJ15jArIsNsiWCwENbvpojq4fVMHLElVcBD8bgVOVcuhwUZ7x3G6Nrb737XA-iL1tM3F1XXBgCd3KZwMeZpxz8-30CAPn0BzHyWJ5ykRnWkS5emKKR4hYsQO3gfV4jra3smvZoFxEHwH9uLqMUPRM7LA\" rel=\"nofollow\" target=\"_blank\">Oncotelic Therapeutics Inc.<\/a><\/p>\n<p>\n        <strong>About BioMedWire<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=83nTgVDEyO9G1miJ8-TKE8LIg1anNPSbbGNGHV8MRpYUY9oZSkeTppgYbrvbhItw-UlChJO5r9KbNQCTiToYY54B9WHLZ3gMg2AyCN4Us3FpDxOBntaqaro43ysbQqfqix4fSqjjZPvxeo5HW5f0TTBN7gUUHD7_AD3awFn0HJgh74rolXJJ0ygh7J1KmrrB_alpRWhWWuEzbI3bY5W75F-ZRsz6mDhMtmrg-1geCrgEe_pXmoXw0G2-sJkXTXay\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>BioMedWire<\/u><br \/>\n        <\/a>\u00a0(\u201cBMW\u201d) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u2p118Sijc7OAPL0_DSW6bTvsm39kKDXKizW34yFQUSJDfBcikM-ckEdKnf7w0c_v4zvwkjDyF0Hn4jvNL4XB0p0b--evYTG-76tpmNzl20QKrpPzcr0Dxs3vTDTGXxKaGT7tn2oHV2lqDVzIc2TT45k6dKgxtIXwGewqyxsZF5xjldYUnStW4TlrRGq1t8W4PCuUNSthx47sy-5e10r5GwfOdPI8jSLMHlji277f9l2F7yyiA78qPqBwnsoMYv_wDFzPClST7j7gzK0QZWe18uq7mw67KJfTYOauK340kiy7rbW1k4Az6hv6mpcEorZw0IwvH3jQaHLpqlQzJdkV9zIlowXpO5prjOdhWRbKds=\" rel=\"nofollow\" target=\"_blank\"><strong><u>Dynamic Brand Portfolio<\/u><\/strong><\/a>\u00a0@\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6spuZuaJxk-uYqS8jDYLji73fSwnaNKbKB8Kvv3Drz68DlSt9GOBaiGp9LQUAUXL3C11SVRAhozVvkvfRSHTaO6SM_yuUPXRe7CV8ioCXbDqQLZ66DxXfE35DhAUvPF_fHePUfzItrwhmOgxPNSs_FgknxVBsbFDdSo550OczocL1zlryOmLPbX4PNedPG2k_n4-BYouxFN7PMlWWJ6eXiBvX3vHJtb_oRfenUjnJG9kLbRXNZ8Fy1b79UAo6wuc\" rel=\"nofollow\" target=\"_blank\"><strong><u>IBN<\/u><\/strong><\/a>\u00a0that delivers<strong>:<\/strong>\u00a0(1) access to a vast network of wire solutions via\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dGAO_O6F-iVGgJC8cc0OkG3Demcu3jV4dbDFVUiAiWn3Tw2GDXChC6sy1CT1Q1R6qvi47uOgrr_B_-JBw68QVQgW2YXmlvX_0WJTLwQ46daZ5JvyJtaXmuCBQuLAurohCd7eveaRA6oI2Y1dhyCbC5Swhx8GLEYCxz5uvFp6RQOAVCBfTjv6QbSmkxrekMxqRKL0IBF5z0M6fq5clCpfX80aj8BujmpN9je8AzNv8C0484c8eiQCUV6wQmu6H5do\" rel=\"nofollow\" target=\"_blank\"><u>InvestorWire<\/u><\/a>\u00a0to efficiently and effectively reach a myriad of target markets, demographics and diverse industries<strong>;<\/strong>\u00a0(2) article and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lmhdxGSppvD2_RNOik-ZhK8_u24abITbpUtn0t4lNtV76n2fb9Zcs9WzBrcCWR3BlS8-NkRdIeiqUGWbhiZ8wVqf4x-Qzl0RTDZ6KyoKPCtGCXA9K9xb51LwLYTnNo5bsztCgggRSBaU8WcMtOV5W1oWp2tH7uz5q_5mtgCFFIxj8Ve24EY4MCJ85z4PUKLSPr6ERaZTZrNrzxebpmInCQziGvEplCB5w6G-2WQalEcwbBRsxn16UKjxTyaVQUw4qcBE5SwxPyhdUhc5cRP89veyq7JNLwnUMnH3-5L2rb-sq2WJ3Kpr0W1SMYsRfjDqrHS2z0QRRqI4nHYppY4YsR_FmPjfk-WRGfoAILCC_v92DLP7H2cirspTTGByNUOSWIHZQfEBMmxICYNSeGIpvd-cNmDpViFhT4gklHy80EYf8qNeFTL9xbPuFRT68xFrtGFld0W0QeUm6OKDI8Aoiw==\" rel=\"nofollow\" target=\"_blank\"><u>editorial syndication to 5,000+ outlets<\/u><\/a><strong>;<\/strong>\u00a0(3) enhanced\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GMmN6bD-SDlejoOdOlyOVOYcsm6m6iISaea95K8GIkdTPEYZnyuLg8tb76HVLACE67I-XD4uktUrFpnmzMtEKNO6Q9Q2aAlAaGmVoRj6abWedWWJAvMPPmemKfX2BMI6tZY5Vm1i2__ebuOpqkq0Oyj3WuuMLhUBYp7j4-95M0fvLL2oQot2i-qMDRyMh9faUtSQKxnrt5kZL5cB14TfUeLIOIF2wpogj1iu-3p5a0Th8FD9glBqLFmGSMtwwhecnoneU9-d1jWzzf_i1PjOp6UoKzRipMdMellzfL4SNErmG6I4RcoRxtdka4H4ukky0G35SfbVyUHiFUnI2dGzViIOm33rarEz1hv544E4swmFI6SFBeOFAfNqXMifnz5H4iRQsXRU7glpRGYZ6Awpjg==\" rel=\"nofollow\" target=\"_blank\"><u>press release enhancement<\/u><\/a>\u00a0to ensure maximum impact<strong>;<\/strong>\u00a0(4)\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nxkQf62i8RxUW21iljAMrXcQBHiY88-C9-PMlAADWZdZMTH4y6x7uTeHEqd08PU1x4O_mpzyZAr18S5KMKw-IQMfCSkQr2Xba4I6TtjLNvHieVHYPWLoimdCtON4MJnow572_a2elr_yLA0PfAOENFsf4l0YDidjLpGJGxax1BL9njAzSQg8Oe8vlnqZya_oyiy4uPnuGvkc7pLVdkZtTqaWn1tHBepLqU8FUSvqdDGtpEHRmaIktI5W_hddIV3MwuQwib-9qySwn6ZLRuitC2rTYZe5aEX0X-VMNPpBTFFm43T4-1BRF9NVUY8gu9gyATYfMiu5hI6qxU9q3NNAtg==\" rel=\"nofollow\" target=\"_blank\"><u>social media distribution<\/u><\/a>\u00a0via IBN to millions of social media followers<strong>;<\/strong>\u00a0and (5) a full array of tailored\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U0cfJ4cWnuUvV3e7dcQVbMRjPYNxa6Zhi2yt04b5OinOYgc3hDDzvmEe74Ccbg9FK0H8PbuqxgdZrsJKfv4s35wWcmVlx_0KE0qPT5UOyhjMawcXBqEXGLnCBHiyof7AviRvE12f6Pk_1fL959Rkbbsqw2WYNvkHxZ46QDS2s71WEhAwBo5n2RDx9GZimvilne9TshdRnmXvGpIw3Ra88BFGIbeus_eIqNKLF6caYemmk9m2C0fNLT2KIFJeI4qixklqwsKMui87GYgpHSy1e4gYenByye2bds1LIjQX4p5RSKblmuXZaM3x-3XQzTyzXkBYbgZOzqNWwaN--B7fIyxPUAS-IbEwUmPXFdp6qJg=\" rel=\"nofollow\" target=\"_blank\"><u>corporate communications solutions<\/u><\/a>. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today\u2019s market, BMW brings its clients unparalleled recognition and brand awareness.<\/p>\n<p>BMW is where breaking news, insightful content and actionable information converge.<\/p>\n<p><strong>To receive SMS alerts from <\/strong><strong>BioMedWire<\/strong><strong>, \u201cBiotech\u201d to 888-902-4192 (U.S. Mobile Phones Only)<\/strong><\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mJdaK1yncAQatrp5d6ixER7DuGi903dvvw9T_YRXokROVhqL8W8r0hpI_2eqVHhnjyJ0t2A1uHaPYRRocjTny9GtQUUpi-zk_ejmDEPFl5NG5exFVN5mGukJp-RvRWQVNAqsGcUVgJLOrnLNZ7B-QcqUABiMN8e0H8ntgwaf-GvbIAZTY7tHiHVaZthno9pYyATeajv-p0M-TlsDGR-g5n7tMqSXvipY8mASu1mL_aTt5fTlLKenrviObA_1Jgn6G4A0armcmDnLFpN7ebWRyNuyOU6VOO4BDaC9PJollXiGpU4BNQdOw-qS06C7WnWQ\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/www.BioMedWire.com<\/u><\/a><\/p>\n<p><strong>DISCLAIMER<\/strong>:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=83nTgVDEyO9G1miJ8-TKE62Yg739LljykhALho7GSWMQFMHwYfdZmTY6pqTH2Ubp2wNqfL6uYKuWLnbsNLHngLtBZn0UutxVi-HKeVjB5nBsWPePVQdh4zm2dv2-2pRN8K85A_ygSWxW16wENNPpgY8_Pr64myWwBEcorDWG8HzvoddEwpqh4QTmpq31kcb3nR_VE02lwJmfqqQnodXx2VZInZGMHYKobOTj4RtSSjGTUT22SJwdySqQ3plV4NoulCU5O5NLFJzduTth3C0VRg==\" rel=\"nofollow\" target=\"_blank\"><strong><u>BioMedWire (BMW)<\/u><\/strong><\/a>\u00a0is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers\/analysts\/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.<\/p>\n<p>The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer\u2019s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer\u2019s securities, including, but not limited to, the complete loss of your investment.<\/p>\n<p><strong>BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.<\/strong><br \/>This release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. \u201cForward-looking statements\u201d describe future expectations, plans, results, or strategies and are generally preceded by words such as \u201cmay\u201d, \u201cfuture\u201d, \u201cplan\u201d or \u201cplanned\u201d, \u201cwill\u201d or \u201cshould\u201d, \u201cexpected,\u201d \u201canticipates\u201d, \u201cdraft\u201d, \u201ceventually\u201d or \u201cprojected\u201d. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company\u2019s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.<\/p>\n<p>Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mJdaK1yncAQatrp5d6ixER7DuGi903dvvw9T_YRXokTCkww4f5_WTf5xd_lFBw8yrK-oc5mxYnX-FgIaFXAAz0aAHOp3nyZlVW-R_-brAXb-BT9o_W3ihUSUv1PiWu4SPxREsdJIcadm_tcTDak73hhE4EavFR2nM0Jwvs8NHkoAKHrhMh-n7czRbytw9rsMqBFAiVW2LprSXug8t9sn8mCtEgXI0luTh_zGMUrEHVm6puP8_NxNAQqernO2Q4ZjYg8E2a_pbBJQj6lNzZ9DcSTXFxHw7wCzBpH1BWwQrjKgpd06bHhuMHN1m-hP-kGSTI6lCRsOyylzCg4Ttc4yUTMRzK7xhv5LKdTEYixMdhc=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/www.BioMedWire.com\/Disclaimer<\/u><\/a><\/p>\n<p>BioMedWire<br \/>Austin, Texas<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DcK1DnHhfDzrZJMBBBbxMy1H7N8sDPVJbGfBxgIZfRODqC65R3ewZOfnqIqZ1AE_9UmldI_oz0GrgulsokMeXLS9Z0dJF5qJdjd7pdLg3qs4uLvr9tP9stQk6qy9P-7ZD7svsPy6ALcJe934n290TlvDzvb9qGWoNM94NJTRPTTwzmBHUo9CyLVE7tjkf2-WW-HBt6zJ6JQakepNA3yVLjMs5KxPL9V7xIFyoZ_7sNInlrlNt_0hZNss6lsB7yxKTEpVk6u7a77G3skhBzrIfA==\" rel=\"nofollow\" target=\"_blank\"><u>www.BioMedWire.com<\/u><\/a><br \/>512.354.7000 Office<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zmyxpBWrDqDIYZbeo3vqbJN_0yEpRLElYj2ZV0cf2diZU4EaU__szxTKd8Nbar6K4WHu-ZyfhcnxzU57jYHBnio0U2mfAkekjSpuLHC73U2JvH2vYoTf16Hb-NJk55FPK8uEV__V7D4I7kpM-E0GbzKPvc7A0Gy8qcDb14Qf2LvJYJrI6G7kPuDt5R5IQe1aSCFL9DrN2UA_6iFv5lAdZRmW12kj62s1uWNcm_vFa2_AX8xg8gsLyJr9q3EWFSq-dTnBF8nW-uaZaNsLAIAbYg==\" rel=\"nofollow\" target=\"_blank\"><u>Editor@BioMedWire.com<\/u><\/a><\/p>\n<p>BioMedWire is powered by\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZA8OCWWV5zt4OvaSr6x9QKy_pkdqk-xmbTiQ4ccDgOSq8N4teS5Zs8JShx2pgL6pjWz5crHpN9V_HLv47cMcrQPx9zW1yze3p2ndBZVcQHSLmPozFmxa01i31Hrn5_Wg0BJf_bJH56-_N0qClJSvFuKGgHS16XPllx9C-PUrrZD4_3yMaGo3xe8wAfm74ncLuqnccwdEAvoSwbkZAFATLMsVrZ6N2pVWVB6vo-5VaHbdNwcE4GQUr5u6XMYeXQ9j\" rel=\"nofollow\" target=\"_blank\"><u>IBN<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWQyNTRmNGUtYjBhYy00MWEwLTk5MmYtZjlhZDEwNTg0NTkxLTUwMDE1NDcxNC0yMDI2LTA0LTIwLWVu\/tiny\/BioMedWire.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) &#8212; BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc.\u00a0(OTCQB: OTLC) (profile), are keenly aware of this evolution and are leveraging their expertise as pioneers in this space. Through its &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952854","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) &#8212; BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc.\u00a0(OTCQB: OTLC) (profile), are keenly aware of this evolution and are leveraging their expertise as pioneers in this space. Through its &hellip; Continue reading &quot;When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T12:33:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech\",\"datePublished\":\"2026-04-20T12:33:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/\"},\"wordCount\":2677,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/\",\"name\":\"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==\",\"datePublished\":\"2026-04-20T12:33:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/","og_locale":"en_US","og_type":"article","og_title":"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech - Market Newsdesk","og_description":"AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) &#8212; BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc.\u00a0(OTCQB: OTLC) (profile), are keenly aware of this evolution and are leveraging their expertise as pioneers in this space. Through its &hellip; Continue reading \"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-20T12:33:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech","datePublished":"2026-04-20T12:33:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/"},"wordCount":2677,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/","name":"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==","datePublished":"2026-04-20T12:33:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MjgzMyM3NTQzOTYyIzUwMDE1NDcxNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/when-science-becomes-an-asset-how-advancing-drug-pipelines-are-driving-real-time-valuation-in-biotech\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952854"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952854\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}